Multi-Specialty Clinical Research

Phase II–IV Studies
At Magno Medical Research Group, we provide comprehensive services designed to support patients, Sponsors, and CROs throughout the clinical trial process. From patient care to regulatory management, our team ensures every study is conducted with quality, efficiency, and compassion.
For Participants
We make clinical trial participation safe, simple, and supportive.
​
-
Study-Related Care at No Cost – Physical exams, laboratory tests, study medication, and procedures are all covered.
-
Compensation – Many studies provide reimbursement for time and travel.
-
Dedicated Support – Our bilingual staff is available to answer questions and guide you through every step of participation.
-
Comfortable Facility – Private exam rooms, flexible scheduling, and free on-site parking.


For Sponsors & CROs
Our site delivers the infrastructure, experience, and capabilities needed for high-quality clinical research.
-
Feasibility & Start-Up – Rapid feasibility turnaround, budget/contract negotiation, and timely IRB submissions.
-
Regulatory Compliance – Dedicated regulatory staff ensuring adherence to ICH-GCP, FDA, and HIPAA standards.
-
Patient Recruitment & Retention – Access to a large, diverse database, physician referral networks, and community outreach strategies.
-
On-Site Facilities – Secure IP pharmacy, laboratory for specimen processing and IATA shipping, exam rooms, and monitor space.
-
Extended Network – Collaborations with imaging centers, infusion clinics, ophthalmologists, gastroenterologists, and biopsy providers for protocol-specific procedures.
-
Data & Quality Oversight – SOP-driven workflows, continuous QA/QC monitoring, and staff trained in sponsor/CRO systems.
Therapeutic Areas
We conduct Phase II–IV trials in a wide range of specialties, including:
Neurology (Alzheimer’s, Parkinson’s, Migraine)
Psychiatry (MDD, Schizophrenia, Substance Use Disorders)
Internal Medicine & Metabolic Disorders (NASH, Obesity, Diabetes, CKD)
Respiratory & Infectious Diseases (Asthma, COVID-19)